	Sign In Sign-Up

Ascomycin Macrolactams

( test position )

Ascomycin macrolactams belong to a new group of immunosuppressive, immunomodulatory and anti-inflammatory agents. Due to their chemical nature they are water-soluble and therefore, in principle, suitable for topical treatment of dermatological disorders.

- -

Ascomycin macrolactam derivative has been approved for short-term and intermittent long-term therapy in the treatment of mild to moderate atopic dermatitis

Ascomycin references

The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils
Discovery of ascomycin analogs with potent topical but weak systemic activity for treatment of inflammatory skin diseases
Studies on an immunosuppressive macrolactam, ascomycin: synthesis of a C-33 hydroxyl derivative
Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin-dependent manner
Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis

[top]


4mg noneto biocompare formulae omd ToxicPlants DictCellBio MolBioDict ( test position ) BioChemical Suppliers

A23187	Actinomycin	Aflatoxin	Anisomycin	Aphidicolin	Ascomycin
Bleomycin	Brefeldin	Cerulenin	Chromomycin	Geldanamycin	Cyclopiazonic acid
Cytochalasin	Forskolin	Fumagillin	Fumonisin	Hypericin	K252a
KT5823	Mitomycin	Nigericin	Ochratoxin	Oligomycin	Mycophenolic acid
Paclitaxel	Patulin	Paxilline	Penitrem	Puromycin	Penicillic acid
Radicicol	Rapamycin	Staurosporine	Sterigmatocystin	Thapsigargin	Tunicamycin
Verruculogen	Wortmannin